Crispr Therapeutics AG (CRSP) Major Shareholder Corp /De/ Celgene Sells 51,282 Shares

Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 51,282 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $18.44, for a total transaction of $945,640.08. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.10, for a total transaction of $1,680,628.10.
  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.25, for a total transaction of $82,062.75.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.75, for a total transaction of $552,802.50.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $520,200.00.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.76, for a total transaction of $5,058,560.00.
  • On Monday, November 20th, Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.02, for a total transaction of $3,018,816.36.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.67, for a total transaction of $265,050.00.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.76, for a total transaction of $1,156,051.68.
  • On Friday, November 10th, Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.28, for a total transaction of $172,800.00.
  • On Wednesday, November 8th, Corp /De/ Celgene sold 16,875 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.06, for a total transaction of $304,762.50.

Shares of Crispr Therapeutics AG (CRSP) traded up $0.01 on Thursday, reaching $18.53. 197,500 shares of the company were exchanged, compared to its average volume of 142,711. Crispr Therapeutics AG has a 12-month low of $11.63 and a 12-month high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The company had revenue of $2.39 million during the quarter, compared to the consensus estimate of $3.61 million. During the same quarter in the prior year, the company earned ($2.77) EPS. The business’s quarterly revenue was up 54.2% on a year-over-year basis. equities analysts forecast that Crispr Therapeutics AG will post -2.46 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its position in shares of Crispr Therapeutics by 459.7% during the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after purchasing an additional 6,560 shares in the last quarter. Capital Investment Advisory Services LLC bought a new position in shares of Crispr Therapeutics during the 3rd quarter valued at about $193,000. Ark Investment Management LLC bought a new position in shares of Crispr Therapeutics during the 2nd quarter valued at about $206,000. Moloney Securities Asset Management LLC bought a new position in shares of Crispr Therapeutics during the 3rd quarter valued at about $235,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Crispr Therapeutics during the 3rd quarter valued at about $288,000. Institutional investors own 24.55% of the company’s stock.

A number of research analysts have recently commented on CRSP shares. Barclays reissued a “buy” rating and set a $29.00 target price on shares of Crispr Therapeutics in a research report on Friday, September 8th. Chardan Capital restated a “buy” rating on shares of Crispr Therapeutics in a research report on Monday, August 14th. BidaskClub lowered shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. SunTrust Banks restated a “hold” rating and set a $16.00 price target on shares of Crispr Therapeutics in a research report on Friday, November 10th. Finally, Cann restated a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, November 9th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $22.38.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/12/07/crispr-therapeutics-ag-crsp-major-shareholder-corp-de-celgene-sells-51282-shares.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply